Related Experiment Video
Updated: May 8, 2025
In vivo Imaging of Optic Nerve Fiber Integrity by Contrast-Enhanced MRI in Mice
Published on: July 22, 2014
MMP-3 and TIMP-1 as prognostic biomarkers in VZV-induced retinal necrosis
Zhujian Wang1, Yu Liu1, Min Zhou2
1Department of Laboratory Medicine, Fudan University Eye Ear Nose and Throat Hospital, Shanghai, China.
Objective:
Acute retinal necrosis (ARN) caused by varicella-zoster virus (VZV) is associated with changes in specific proteins in the eye's fluid, particularly matrix metalloproteinase-3 (MMP-3), an enzyme that breaks down tissue structures, and tissue inhibitor of metalloproteinase-1 (TIMP-1), which regulates MMP activity. This study aims to investigate how these proteins correlate with the progression of ARN.
Methods:
We analyzed aqueous humor samples from 33 patients with ARN and 23 control patients with virus-negative uveitis. MMP-3 levels were measured using immunoturbidimetry, and TIMP-1 levels were determined using an enzyme-linked immunosorbent assay. We examined the relationships between these protein levels and clinical findings using statistical correlation methods.
Results:
MMP-3, TIMP-1 were significantly higher in the aqueous humor of ARN patients compared to the controls (P<0.0001). Correlation analysis revealed a significant correlation between MMP-3 levels and TIMP-1 (r = 0.460, P = 0.007). The upregulation of MMP-3 and TIMP-1 was found to parallel VZV DNA load and IL-6 levels. Additionally, they exhibited negative correlation with best corrected visual acuity (BCVA) and positive correlation with the percentage of active retinal necrosis area.MMP-3 was markedly enhanced in all 14 cases of retinal detachment (RD), whereas TIMP-1 levels were significantly reduced in the same cohort of eyes. Patients with initial higher TIMP-1 levels have a significantly increased risk of developing RD, with a hazard ratio (HR) of 3.152 (95% CI, 1.082-9.18).
Conclusion:
The imbalance between MMP-3 and TIMP-1 may play a critical role in the development and severity of ARN. Measuring these proteins in the eye's aqueous humor could be valuable for assessing disease progression and guiding treatment strategies, potentially improving outcomes for patients with virus-induced retinal diseases.
Insights
Elevated matrix metalloproteinase-3 (MMP-3) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in aqueous humor correlate with acute retinal necrosis (ARN) severity and progression. These protein levels may aid in assessing disease and guiding treatment for VZV-induced retinal conditions.
Area of Science:
- Ophthalmology
- Virology
- Biochemistry
Background:
- Acute retinal necrosis (ARN) is a severe intraocular inflammation often caused by varicella-zoster virus (VZV).
- Specific protein changes in ocular fluids, including matrix metalloproteinase-3 (MMP-3) and tissue inhibitor of metalloproteinase-1 (TIMP-1), are implicated in ARN pathogenesis.
Purpose of the Study:
- To investigate the correlation between MMP-3 and TIMP-1 levels in aqueous humor and the clinical progression of ARN.
- To assess the potential of these proteins as biomarkers for ARN severity and treatment guidance.
Main Methods:
- Aqueous humor samples were collected from 33 ARN patients and 23 controls with virus-negative uveitis.
- MMP-3 and TIMP-1 levels were quantified using immunoturbidimetry and ELISA, respectively.
- Statistical correlation analyses were performed to link protein levels with clinical findings, VZV DNA load, and IL-6.
Main Results:
- MMP-3 and TIMP-1 were significantly elevated in ARN patients compared to controls (P<0.0001).
- Higher MMP-3 and TIMP-1 levels correlated with increased VZV DNA load, IL-6, and ARN severity (retinal necrosis area).
- Elevated MMP-3 and reduced TIMP-1 were associated with retinal detachment (RD), with higher TIMP-1 predicting increased RD risk (HR=3.152).
Conclusions:
- An imbalance between MMP-3 and TIMP-1 appears critical in ARN development and severity.
- Measuring MMP-3 and TIMP-1 in aqueous humor may serve as a valuable tool for disease assessment and treatment strategy development in viral retinitis.
